Insmed Incorporated (INSM) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Bridgewater, NJ, 미국. 현재 CEO는 William H. Lewis.
INSM 을(를) 보유 IPO 날짜 2000-06-01, 1,271 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $33.07B.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial product, ARIKAYCE, is an inhaled antibiotic combination therapy approved for treating Mycobacterium avium complex lung disease in adults. Insmed's pipeline includes Brensocatib, an oral inhibitor of dipeptidyl peptidase 1 being developed for bronchiectasis and neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treatment candidate for pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company specializes in addressing unmet medical needs in rare respiratory and systemic diseases.
